Welcome to our dedicated page for Cabaletta Bio news (Ticker: CABA), a resource for investors and traders seeking the latest updates and insights on Cabaletta Bio stock.
Cabaletta Bio, Inc. (symbol: CABA) is a clinical-stage biotechnology company dedicated to the discovery and development of engineered T cell therapies for patients suffering from B cell-mediated autoimmune diseases. Utilizing its proprietary Chimeric AutoAntibody Receptor (CAAR) and Chimeric Antigen Receptor T cells for autoimmunity (CARTA) technologies, Cabaletta aims to provide targeted, effective, and potentially curative treatments.
The company's flagship product candidate, DSG3-CAART, is in Phase I clinical trials for treating mucosal pemphigus vulgaris, an autoimmune blistering skin disease. Other promising candidates include MuSK-CAART for myasthenia gravis and FVIII-CAART for a subset of patients with hemophilia A. Cabaletta is also actively developing DSG3/1-CAART for mucocutaneous pemphigus vulgaris, with several products in various stages of preclinical and discovery phases.
In recent developments, Cabaletta Bio received approval from the U.S. FDA for its Investigational New Drug (IND) application for CABA-201, a fully human CD19-CAR T cell investigational therapy for generalized myasthenia gravis (gMG). This expands their portfolio into neurology, complementing prior clearances for lupus, myositis, and systemic sclerosis. The upcoming Phase 1/2 clinical trial for CABA-201 aims to test its efficacy in treating gMG patients, potentially offering a groundbreaking one-time dose treatment.
Furthermore, Cabaletta has secured multiple Fast Track Designations from the FDA for CABA-201 in conditions like dermatomyositis and systemic sclerosis, facilitating expedited development and review. These designations highlight the critical unmet needs in these patient populations and amplify Cabaletta’s commitment to pioneering advanced therapies.
Based in Philadelphia, PA, Cabaletta Bio continues to advance its innovative pipeline, guided by robust scientific research and strategic collaborations. The company is well-positioned financially, with adequate resources to fund its operations into the first half of 2026. Cabaletta's mission is to harness the power of engineered T cells to unlock transformative therapies, offering patients durable, drug-free remissions and improved quality of life.
Cabaletta Bio (CABA) announced positive acute safety data from the first cohort of its Phase 1 DesCAARTes™ clinical trial for DSG3-CAART, targeting mucosal-dominant pemphigus vulgaris. As of April 30, 2021, no dose limiting toxicities (DLTs) or clinically relevant adverse events were reported among the three patients dosed. The company anticipates initiating the second dose cohort after confirming safety data from the first cohort. Acute safety results for the second and third cohorts are expected in Q3 and Q4 2021. A conference call is scheduled for today at 8:30 a.m. ET to discuss these results.
Cabaletta Bio is a clinical-stage biotechnology firm focused on engineered T cell therapies for patients with B cell-mediated autoimmune diseases. On April 14, 2021, at 3:00 p.m. ET, CEO Steven Nichtberger will participate in a fireside chat at the 20th Annual Needham Healthcare Conference. The live webcast will be accessible on the company’s website and will remain available for replay for 90 days. The lead product candidate, DSG3-CAART, targets mucosal pemphigus vulgaris and has received Fast Track Designation from the FDA.
Cabaletta Bio, Inc. (CABA) reported its financial results for Q4 and FY 2020, highlighting significant milestones in its clinical trials. The company successfully dosed the first patient in a Phase 1 trial for DSG3-CAART, targeting mucosal pemphigus vulgaris, without dose limiting toxicities. Financially, R&D expenses increased to $21.4 million in 2020, up from $11.7 million in 2019. The company ended 2020 with $108.7 million in cash, down from $136.2 million a year earlier, ensuring funding through Q3 2022. Key milestones are anticipated in 2021, including additional trial data and an IND submission for MuSK-CAART.
Cabaletta Bio, Inc. (Nasdaq: CABA), a biotechnology firm specializing in engineered T cell therapies for B cell-mediated autoimmune diseases, will participate in two investor conferences in March 2021. The first is the Cowen & Co. 41st Annual Health Care Conference on March 3, where CEO Steven Nichtberger will engage in a cell therapy panel. The second is the H.C. Wainwright Global Life Sciences Conference on March 9, featuring a pre-recorded fireside chat. The discussion will be available on-demand post-conference on the company’s website for 90 days.
Cabaletta Bio, a clinical-stage biotechnology firm listed on Nasdaq as CABA, announced that its CEO, Steven Nichtberger, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 5:20 p.m. ET. A live webcast of the event will be available on the company's website and a recording will be accessible for 90 days post-event. Cabaletta is focused on engineered T cell therapies for B cell-mediated autoimmune diseases with its lead candidate, DSG3-CAART, currently in clinical trials.
Cabaletta Bio, a clinical-stage biotechnology company (Nasdaq: CABA), focuses on engineered T cell therapies for B cell-mediated autoimmune diseases. CEO Steven Nichtberger will present at two investor conferences on January 11, 2021. The presentations will be available via webcast on the company's website, starting at 6:00 a.m. and 7:00 a.m. ET respectively. The company's approach utilizes Chimeric AutoAntibody Receptor T cells, targeting specific autoantibody-producing B cells. Its leading candidate, DSG3-CAART, is in a phase 1 clinical trial for mucosal pemphigus vulgaris, with Fast Track Designation from the FDA.
Cabaletta Bio, Inc. (Nasdaq: CABA) achieved a significant milestone by infusing the first patient with its DSG3-CAART therapy during the DesCAARTes™ Phase 1 clinical trial. This trial aims to treat mucosal-dominant pemphigus vulgaris (mPV) and explores CAAR T cell technology for autoimmune diseases. DSG3-CAART could provide a more targeted and durable treatment option compared to current therapies that often induce broad immunosuppression. The trial will assess safety, tolerability, and early efficacy signs with an expected enrollment of 30 subjects across multiple sites in the U.S.
Cabaletta Bio, focused on engineered T cell therapies for B cell-mediated autoimmune diseases, will participate in two investor conferences in December 2020. Steven Nichtberger, M.D., the CEO, will partake in a pre-recorded chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 2 and a live discussion at the Evercore ISI 3rd Annual Virtual HealthCONx Conference on December 3. The company’s pipeline includes DSG3-CAART, which targets mucosal pemphigus vulgaris and has received FDA Fast Track Designation. Webcast replays will be accessible for 90 days on their website.
Cabaletta Bio, Inc. (CABA) reported its Q3 2020 financial results, highlighting progress in its clinical programs. The company is actively enrolling patients in its Phase 1 trial for DSG3-CAART, aimed at treating mucosal pemphigus vulgaris, expecting to report acute safety data in the first half of 2021. Q3 R&D expenses rose to $5.7 million from $3.2 million in Q3 2019, and G&A expenses increased to $2.8 million from $1.8 million. As of September 30, 2020, cash and equivalents stood at $118.1 million, down from $136.2 million at year-end 2019, enough to fund operations through Q3 2022.
Cabaletta Bio, a clinical-stage biotechnology company focused on engineered T cell therapies for B cell-mediated autoimmune diseases, announced that CEO Steven Nichtberger will speak at three investor conferences in October 2020. The presentations include:
- Stifel 2020 Immunology and Inflammation Virtual Summit on October 1 at 3:00 p.m. ET.
- Jefferies Virtual Cell Therapy Summit on October 5 at 8:30 a.m. ET.
- Chardan 4th Annual Genetic Medicines Conference on October 6 at 11:30 a.m. ET.
Webcasts will be available on the company’s website.
FAQ
What is the current stock price of Cabaletta Bio (CABA)?
What is the market cap of Cabaletta Bio (CABA)?
What is Cabaletta Bio's primary focus?
What are some of Cabaletta Bio's key product candidates?
What is CABA-201 and why is it significant?
Has Cabaletta Bio received any regulatory designations?
Where is Cabaletta Bio headquartered?
What is the current financial condition of Cabaletta Bio?
What stages are Cabaletta Bio's clinical trials in?
What makes Cabaletta Bio's technology proprietary?
What recent achievements has Cabaletta Bio made?
How does Cabaletta Bio aim to impact patient care?
